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Abstract
In the development of medical drug delivery systems, attention has been increasingly focused on
slow- or controlled delivery systems in order to achieve an optimal therapeutic effect. Since the
administration of drugs often requires a defined or minimum effective dosage in the human body,
more conventional delivery systems such as tablets require relatively high doses, which can result
in undesired toxic effects. Subsequent degradation of the drug in the human body will result in a
drug concentration below the minimum effective level. Furthermore, there are situations where oral
administration is less advisable, such as in cases of prolonged treatment or with people that are
forgetful, which again results in ineffective treatment. Textile slow-release systems have the
potential to overcome these negative aspects. Drugs containing transdermal patches for ex-vivo
applications are already familiar; however, this paper will not deal with such applications, but with
more advanced in-vivo textile slow-release systems. Due to enormous progress over the years in
the fields of supramolecular chemistry, nanotechnology, and polymer science & technology, a
number of promising drug delivery technologies have been developed. This review will focus on
the opportunities of textiles bearing cyclodextrins, aza-crown ethers or fullerenes, as well as ion-
exchange fibres, drug-loaded hollow fibres, textiles treated with nanoparticles and fibres with
bioactive compounds in their embodiment. In this paper, the delivery systems will be discussed
and compared in terms of biostability, biodegradability, controllability, toxicity, carcinogenicity,
interface reactions, material costs and the fabrication process.
Keywords: slow release systems, drug delivery, medical, cyclodextrins, aza-crown ethers,
fullerenes, ion-exchange fibres, hollow fibres, nanoparticles, entrapment, encapsulation.
Introduction
Over the years, people have always tried to improve the quality and length of life, and with success.
Positive developments in hygiene and nutrition have increased the average lifespan by several years.
The growth in medical knowledge has also greatly contributed to this, and developments are still
ongoing. Besides searching for solutions to medical problems, many attempts have been made to
improve the comfort of application. Textile systems can be useful in this respect.
A specific aspect within the medical field is the delivery of drugs. Pills, ointments, injections and
suchlike are already familiar; though these are useful in many cases, situations can be thought of in
which other systems would be more applicable. In oral delivery systems (e.g. tablets, pills, capsules),
the drug is absorbed in the stomach or intestinal tract [1, 2]. As some drugs become metabolised,
either there or in the liver, they lose their efficacy before being able to fulfil their medical purpose.
Consequently, relatively high doses are necessary to achieve an effect, which might give rise to liver
toxic metabolites [1, 2]. Delivery through the skin circumvents the liver passage, allowing drug
dosages to be reduced. Ointments are an alternative, but only for those therapeutic agents that will
give no side effects in case of overdose [1]. Moreover, there are situations where oral administration is
less applicable or impractical, e.g. with children, people with swallowing difficulties or people who are
forgetful, for example because of dementia. Transdermal (through the skin) and in-vivo (inside the
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body) drug delivery systems constitute a good alternative in these situations. Finally, with prolonged
drug treatment, these systems are more preferable than daily injections or intake of pills.
One general benefit obtained from the use of textile materials is protection. Over the years, wearing
comfort and the quality of textiles have improved, and textile materials now form an important aspect
of our everyday lives. Besides the material itself, the structure is important. While dependent on the
fabrication process, textile materials are often permeable, breathing structures, and usually treated to
have an absorptive capacity. Therefore, textile materials have also found applications in the medical
field. Their ‘breathing’ capability especially makes textile materials a useful basis for ex-vivo (outside
the body) applications. Moreover, as people are used to wearing textile materials, it seems logical to
examine these materials as a possible basis for drug delivery systems.
Over the years, a number of delivery methods have been developed. So-called transdermal patches
are already familiar. Most such patches consist of multi-layer systems, in which in addition to an
ointment (or other drug-containing substance), a regulatory system (e.g. a membrane) is used. This
paper will not discuss these kinds of systems, but will essentially focus on the following promising
systems:
• textiles bearing cyclodextrins;
• textiles bearing aza-crown ethers;
• textiles bearing fullerenes;
• ion-exchange fibres;
• drug-loaded hollow fibres;
• textiles treated with nanoparticles;
• fibres with bioactive compounds in their embodiment.
Because of their application in medicine, the delivery systems are mainly discussed in terms of
features such as biocompatibility and controllability. Other aspects, which are usually important in
textiles, e.g. colour fastness and washability, are not included in this study.
Practically the most important aspect of a drug delivery system is its biocompatibility, which nowadays
is defined in the following terms: “the ability of a material to perform with an appropriate host response
in a specific application”. Important elements included in biocompatibility are toxicity, carcinogenicity
and related issues as mutagenicity (inducing changes in genetic material that are transmitted during
cell division) and teratogenicity (the ability or tendency to produce anomalies of formation). For
biodegradable materials, not only should the parent material be harmless, but the degradation
products as well. For most substances, the skin forms a natural barrier in entering the body, but with
in-vivo applications extra care should be taken in order to avoid the introduction of harmful substances
into the body. A second aspect of biocompatibility is the product’s biostability and biodegradability.
Depending on the application, a more or less biostable product is desirable. A general approach is that
in-vivo applications have to be biodegradable, removing the need for an extra operation to remove the
material. For many ex-vivo applications, biostability is desirable, although ultimately biodegradability
would be beneficial, considering waste disposal. The interactions at the interfaces of the textile
material and body tissue, e.g. the skin, form the third important biocompatibility aspect in developing a
proper textile-based drug delivery system. Systems with excellent controllable delivery are of no
interest if they lead to considerable irritation of the skin at the same time.
Another important aspect of a delivery system is its controllability. As mentioned before, in some of the
conventional systems the risk of overdose is present. Using a slow-release delivery system, with
which the drug can be delivered in a controlled way, might constitute a solution. Experiments will have
to be performed to bring system release patterns into view. Preferably, a system should be
controllable in such a way that release is possible within a certain range; that is, with any given
system, different release patterns should be feasible responding to an individual patient’s need.
Although difficult to quantify in the developmental stage, the material costs of a system are not
irrelevant – there is no use in developing a system in which the benefits are cancelled out by the
costs. In developing medical applications, costs are often ‘allowed’ to rise, so long as a unique product
with a highly desired function is the result. However, in comparing different systems with virtually the
same goal, the cost aspect cannot be neglected; for this reason, a short discussion on this topic is
included here. Related to the cost aspect is the production process. Conventional production
techniques will in most cases be beneficial in comparison to specially developed new techniques;
generally speaking, the more complicated the technique, the higher the costs. Therefore, differences
in system processing will be discussed and compared. Unfortunately , it will be difficult to make a
quantitative analysis for many factors, and only qualitative considerations are given when comparing
different textile slow-release systems.
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Drug delivery systems
Cyclodextrins
Textiles bearing cyclodextrins consist of ordinary textile materials upon which cyclodextrin molecules
have been fixed. Cyclodextrins are cyclic (α-1,4)-linked oligosaccharides, built from a number of D-
glucose units. The generally most common forms are the so-called α-, β- and γ-cyclodextrins (see
figure 1 for an example). Because of the combination of a hydrophobic interior and a hydrophilic
exterior, cyclodextrins can be useful components in the complexation of (hydrophobic) drugs. The ring
size of cyclodextrins can be varied since different cyclodextrins have cavities of a different size, but
still only selected groups of drug molecules that fit in the cavities can be used in complex formation. It
is stated that complex formation is largely independent of the chemical properties of the drug molecule
[3], making the group of drugs that are compatible with a particular cyclodextrin quite large. This is
underlined by the different types of drugs that have been investigated in drug-cyclodextrin complexes,
varying from neutral to ionic and from basic to acidic [4]. Furthermore, several modifications of the
parent cyclodextrins are possible. The derivatives can be reactive (e.g. cyclodextrin with a
monochlorotriazinyl (MCT) group), more hydrophilic (by means of hydrophilic side groups, such as
hydroxypropyl and hydroxyethyl), less hydrophilic (by means of lipophilic side groups, such as
ethylhexyl glycidyl) or ionic (by means of ionic side groups, such as hydroxypropyl trimethyl
ammonium chloride) [5].
Cyclodextrins have been successfully immobilised upon textile fabrics. There are a number of ways to
attach the molecule to the textile material, which can be classified into two main categories, physical
and chemical attachment. A specific example, which can be considered more as entrapment than
attachment, is when cyclodextrin is spun into the fibre. This can only be achieved with materials
whose fibres are made using melt or solution spinning, e.g. polyamide-6. Cooling the fibre leaving the
spindle in a shock-wise manner causes the cyclodextrins to migrate to the surface [6], thus locating
the cyclodextrins in the fibre’s outer sphere. This will keep the cyclodextrin cavities accessible to the
drug molecules. A second example concerns cyclodextrin derivatives bearing so-called ‘anchor
groups’. Anchor groups are able to penetrate textile fibres when the latter are in their amorphous state.
These groups are mainly hydrophobic ‘tails’, such as alkyl or aryl groups [6], which fit excellently into
the fibre’s hydrophobic inner environment. The hydrophilic outer surface of the cyclodextrin will
prevent complete penetration into the fibre; hence, the functional cavity remains accessible on the
fibre’s surface [7]. Upon lowering the temperature (below Tg), the fibre polymers are restricted in their
motion and the anchor groups are captivated, thus fixating the cyclodextrins [4, 6].
When cyclodextrin derivatives are ionic in nature, the fixation with a textile fabric may be based on
electronic interactions. A specific example is the interaction of HPTMAC1-β-cyclodextrin with
polyacrylonitril fibres [4].
The chemical fixation of cyclodextrins can be achieved by reaction of textile fibre functional groups
with the functional groups in the cyclodextrin. A straightforward example is the reaction of the
accessible cyclodextrin hydroxyl groups with (among others) hydroxyl, carboxyl, amide or other acidic
or basic groups [6]. Cyclodextrin derivatives can have other functional groups, such as MCT, which
reacts through substitution of the chlorine atom by a negative polymer side group [4]. Another
comparable fixation uses a third molecule as a kind of intermediate between fibre and cyclodextrin, for
example a polymer. Upon polymerisation, these compounds react with both the hydroxyl groups of the
cyclodextrins and a textile fibre functional group, e.g. the hydroxyl group of cellulose. Furthermore,
some network formation takes place, which leads to a combined fixation and entrapment of the
cyclodextrins [6].
The methods for treating the textile are thus quite simple. The method using anchor-bearing
cyclodextrins is especially useful, since no fixation agent is needed, making it possible to use
conventional textile treatment techniques and apparatus [4]. Furthermore, this method has virtually no
limitations with respect to the textile materials that can be used.
Several tests [4, 8] have shown that the complexing power of cyclodextrins was maintained upon
fixation. Hence, textiles treated with cyclodextrins can be used as drug carrying systems.
Fixating cyclodextrins upon a textile material does not only alter the complexation power of the
system. With derivatives containing large hydrophobic/lipophilic side groups, the diffusion time for a
water droplet is increased, whereas hydrophilic groups have the opposite effect. The surface
resistance is changed by the fixation of cyclodextrin derivatives. The surface resistance decreases
when increasing the amount of alkyl groups on the surface [4]. Another important change is the
                                                
1 HPTMAC: hydroxypropyl trimethyl ammonium chloride
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reactivity of treated fabrics, as the cyclodextrins introduce reactive hydroxyl groups to the textile
surface.
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Figure 1. Structure of β-cyclodextrin
Aza-crown ethers
An alternative to the attachment of cyclodextrins to textile materials is the attachment of aza-crown
ethers. The data on these kinds of systems are less detailed than for cyclodextrin systems, but still a
few comments can be made. Aza-crown ethers are neutral, macrocyclic polyether molecules, in which
the oxygen atoms are partially or completely replaced by nitrogen. In contrast with cyclodextrins,
which have a 3D-structure, aza-crown ethers in their basic form are only 2D. The secondary amine
groups are possible substitution spots. The molecules are capable of forming stable complexes with
metal ions, in particular the so-called transition metals. Selectivity is governed by the (fixed) crown ring
diameter, the number of heteroatoms in the ring, the ion diameter and the charge density of the cation
[9]. Aza-crown ethers can be fixed upon textile materials without loss of the crown ether’s complexing
power. This was tested by treating cotton, PET and PA-6.6 with aza-crown ether 22DD (ACE 22DD)),
ACE (22TT), ACE (22TTp(NO2)2) and ACE (22TrTr) [9]. See figure 2 for examples of the different
structural formulas.
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Figure 2. Several examples of the different structural formulas of some aza-crown ethers
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Fixation is achieved by treating the materials with a flowing ACE-solution in trichloromethane (ACE
(22TrTr) in combination with cotton) or water (the other systems) and heating [9]. Again, two main
types of fixation can be distinguished, namely a chemical reaction of side groups of the aza-crown
ether and the fibre, and the ‘anchoring’ of the aza-crown ethers through hydrophobic side groups.
Increasing the temperature leads to an increased amount of fixed ligands, which is explained by the
facilitated penetration of the hydrophobic tails at elevated temperatures.
Fullerenes
Another way to fix macromolecules is by the use of fullerenes. Fullerenes are a so-called allotropic
form of carbon; the material consists of only carbon atoms. A well-known example is C60, which is
more or less shaped like a football. Inclusions of helium and other metal ions in the fullerene inner
cavity have been reported. Furthermore, fullerenes themselves can act as a guest molecule in
complexation with macrocyclic ligands, such as cyclodextrins [10]. The fullerene groups can be used
as a starting point for self-assembling molecular layers, for example by combining them with
cyclodextrins. Additionally, bound fullerenes are usually capable of reacting with other compounds.
One possibility is a reaction with aza-crown ethers, which in their turn can bind other compounds and
so on. In this way, layers with complexing capacity can be built [10]. Because of their olefinic,
electrophilic character, fullerenes react in several addition reactions, e.g. in nucleophilic addition of
amines. This can be used to achieve the permanent fixation of fullerenes to polymers such as PET,
PA-6.6 and wool, which contain amine elements.
Ion-exchange fibres
As the name suggests, ion-exchange fibres are capable of exchanging ions. The principle has been
known for quite some time and these fibres are already used in many applications, e.g. in wastewater
treatment. Ion-exchangers bury either a positive or a negative electric charge, which is compensated
by (mobile) counterions of opposite polarity. Mobile ions of the same sign (co-ions) can also be
present. In cationic fibres, the bound ionic groups are formed by e.g. –SO3-, -COO-, -PO3- and -AsO3-.
Anionic groups are those such as –NH3+, -NH2+, -NH+ and –S+. The principle of ion-exchange is based
on the electroneutrality requirement. The exchange is generally a diffusional process, sensitive to
concentration gradients, and the rate-determining step in ion exchange is the diffusion either within the
exchanger itself or in the so-called diffusion boundary layer. Usually ion-exchangers take up some
counterions in preference to others. This fact can be used in controlling the exchange [11]. Drug
stability during storage improves upon bonding them in ion-exchange fibres.
The drugs act as the mobile counterion. They can be released by ions in bodily fluids, though this
might disturb the homeostasis. Furthermore, in ex-vivo applications, the amount of such ions will
probably be too low to achieve sufficient drug release. Hence, a co-solution of a salt, such as sodium
chloride or sodium phosphate [12], is used. The sodium ions will replace the drug ions. and the latter
will combine with (in this case) the chloride or phosphate ions. The salt can be encompassed in a gel
(based for example on gelatin, agar or polyvinyl alcohol), which is then brought into contact with the
textile fibre loaded with the drug. The salt will diffuse through the gel and the fibre, and thus release
the drug [12]. An interesting application may be to use ion-exchange fibres for the regulated in-vivo
delivery of insulin, in order to treat diabetes mellitus [13, 14]. In literature, chemically bonded drugs are
mentioned as a variation on ionic drug-ionic fibre interaction [14].
Ion-exchange fibres suitable for drug delivery are already commercially available. Examples are the
so-called Smopex® fibres, which consisting of a polyethylene backbone grafted with other polymers,
e.g. poly(styrenesulphonic acid) (Smopex®-101) polyacrylic acid (Smopex®-102) or polyamide
(Smopex®-108) [2, 11]. Besides using the commercially available ion-exchange fibres, it is also
possible to graft ion-exchange groups to a (textile) fibre. Fibres suitable for this purpose include
cellulosics and wool, but also synthetic fibres like polyethylene, polystyrene, polyacrylonitril, polyamide
and carbon fibres [12]. The amount of functional groups grafted onto the fibres affects its loading
capacity.
Hollow fibres
Hollow fibre systems can be seen as small tubes which can be filled with a drug. The fibre wall usually
consists of a permeable membrane that can be used in controlling drug release. The fibres are
advantageous in two ways, as they have a high surface area to volume ratio and a high loading
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flexibility. The system can comprise hollow tubes filled with a liquid drug or a drug solution [15].
Another possible form is a hollow fibre in combination with (an) ion-exchange resin(s) [16]. Also, drug
crystals dispersed in a polymer core [17] can be used. In yet another variety, drugs are dissolved in
such a core [17]. The systems in which the drug is bound into a polymer are prepared by mixing the
drugs with a polymer material, in order to give a drug-loaded core granulate. If desired, different
drug/polymer granulates can be mixed. The mixture is heated in order to melt the polymer; the drug is
dissolved in the polymer. After cooling, the mixture is granulated again. These granulates are used in
co-extrusion together with granulates of the polymer which is to form the fibre membrane. Both
granulates are molten (but not mixed), and by accurately controlling the two polymer flows through a
spinneret, a coaxial fibre combining the polymer core and the fibre membrane is formed [17]. When
drug crystals are desired, the melting of the polymer-drug combination before co-extrusion is skipped.
Nanoparticles
In the treatment of textile with nanoparticles that contain a functional agent (which can be a drug), the
nanoparticles are permanently fixed on a textile fabric through chemical bonds, either by direct
reaction of a particle side group and the textile, or by means of a linker molecule. The nanoparticle
encapsulation is used to circumvent possible alterations and loss of functionality of the agent, which
could be the case in a direct reaction between the agent and the textile. However, linkers for direct
chemical attachment and also useful in controlled release are difficult to engineer, and must be
developed for the various agents individually [18].
The nanoparticles consist of a drug, either surrounded by a synthetic, polymer shell or contained
within a synthetic, 3D polymer matrix, both micrometric to nanometric in size. Encapsulation can be
achieved by several methods, e.g. interfacial polymerisation, microemulsion polymerisation,
precipitation polymerisation and diffusion. In general, the drug is brought into contact with a set of
monomers, oligomers or polymers. These assemble around the payload; polymerisation will give the
final particles. An alternative way is to prepare the nanoparticle in the absence of the drugs, which are
absorbed by the nanoparticles following afterwards [18].
A wide range of applicable monomers, oligomers and polymers is available. Some very useful
systems are those containing amine, hydroxyl or sulph-hydryl monomers or polymers combined with
amine-, hydroxyl- or sulphhydryl-reactive monomers or polymers. Both hydrophobic and hydrophilic
monomers can be used; the choice depends on the drugs to be encapsulated [18]. As an extra option,
systems can be copolymerised with soft or rubbery monomers or polymers (e.g. acrylates or
methacrylates), to improve wearing properties such as ‘skin softness’ and wrinkle and abrasion
resistance [18]. The monomer or polymer systems used contain at least one component able to react
with a textile material even after polymerisation. Wool and other animal fibres contain hydroxyls,
amines, carboxylates and thiols. Synthetic fibres usually have a limited number of reactive groups.
The same holds for cellulose and its derivatives as well as other plant materials, which have to react
through their hydroxyl groups. In order to increase the possible particle-textile combinations, a
bifunctional molecule can be used, for example to link an amine-reactive particle with cellulose (which
contains no amine groups) [18]. For particle fixation, the textile material is exposed to a solution,
dispersion or emulsion of the textile-reactive particles, by conventional methods such as soaking,
dipping, spraying, fluid-flow or padding [18]. A catalyst may be present in the medium. The actual
fixation takes place in the curing stage, which can take place while the textile is still in contact with the
particle solution (dispersion, emulsion), but preferably after the drying stage. In the case of using a
linker molecule, the textile material may first be treated with the linker and subsequently with the
particle solution [18]. The contact time can vary widely, from seconds to days, as can temperatures
and pressures [18].
Drugs incorporated in fibres
Another approach in creating textile drug-delivery systems is processing the drug in the fibre’s
preparation stage. With the hollow fibres, there was still a distinct separation into fibre (the membrane
wall) and drug (the core). Yet another way of incorporating drugs into fibres is to suspend or dissolve a
bioactive compound (in particular a drug) into the polymer solution used to produce the fibres. If a
bioactive compound is to be incorporated within or inside the polymer fibre, polymer selection is based
upon the solubility of the drug in the polymer solution. If the drug is to be located between the fibres,
this is of no concern. Instead, the drug can be suspended in the polymer solution before the actual
spinning. The spinning will give nonwoven meshes of nano- and micron scale fibres. These fibres can
be processed into matrices, linear assemblies and braided or woven structures, or be used in film
181
coating. Fibres can be spun from any polymer which can be dissolved in a solvent. This includes non-
degradable polymers such as polyethylene, polyurethanes and polyethylene vinyl acetate copolymers,
but also biodegradable polymers such as poly(lactic acid), poly(glycolic acid), poly(orthoesters) and
poly(phosphazenes) [19]. An interesting development related to this kind of system is the synthesis of
a biodegradable polymer with a drug incorporated into the polymer backbone. Upon degradation of the
polymer, the drug is released again. It has been shown that polymers can be developed which are
more easily degraded in the presence of certain enzymes, e.g. enzymes highly presence at infection
spots. Hence, the drug release would be more or less ‘triggered’ by the infection (in this case) [20]. A
serious drawback reported in the literature is the system’s low efficiency. This can be explained by the
fact that upon degradation of the polymer, the degrading ‘scissions’ are not always made perfectly at
each junction of drug and polymer, and a number of non-functional rest products are formed [20].
These kinds of polymers have not yet been tested for processing into fibres and textile materials, but it
might be an interesting option to experiment on this point. When doing so, it is not necessary to
restrain oneself to drug-containing polymers only; for improvement of mechanical properties, for
example, combinations with other (biodegradable) polymers can be made.
Toxicity and carcinogenicity
Cyclodextrin-bearing textiles can be considered as not harmful. Conventional textile materials can
form the basis of the system, and the only harm could lie in the cyclodextrins. Detailed studies of the
toxicity, mutagenicity, teratogenicity and carcinogenicity of some cyclodextrins and their derivatives
have been made. These substances were potentially harmful only in extremely high concentrations,
and no acute toxicity has been observed [7]. More detailed information on specific cyclodextrins can
be found in the literature [21]. In general, they are considered to be non-toxic [22].
For aza-crown ethers, little specific data on toxicity and carcinogenicity has been found. It has been
stated that aza-crown ethers are less toxic than their crown ether equivalents, due to the reduced
influence on potassium leakage into and sodium leakage out of cells. Complexed ligands are much
less toxic than uncomplexed ones. Besides, as aza-crown macrocycles have been investigated for
medical purposes for a long time, e.g. for their use in antitumour treatment, in treatment of kidney
stones and even as a drug element, it can be assumed that their toxicity and carcinogenicity is
acceptable with respect to medical limits [23]. More specific data (although very limited) on the aza-
crown ether used in the specific example described above (ACE (22DD)) can be found on the
Internet2. Upon exposure, no harmful effects have been indicated in the information available. The
material is not listed as being carcinogenic.
For fullerene-bearing textiles, it could be stated that these materials are not highly toxic, since free
fullerenes are applied in other medical fields as well, implying a harmless effect of this group [24, 25].
In literature found on ion-exchange fibres, no comments are made on toxicity. As the polymer base
materials are formed by common, non-toxic and non-carcinogenic materials, toxicity and
carcinogenicity would have to stem from the ion groups attached to the polymer backbones. As the
groups are bound to the polymer, no harm is to be expected from free ionic groups. Furthermore, the
ion groups are neutralised by a suitable counterion ‘at all times’, be it either a drug or an electrolyte
ion, hence the possible negative effect is cancelled. For in-vivo applications, the ion exchange fibre
might present problems when it disturbs the homeostasis. Confining the use of ion-exchange fibres to
ex-vivo applications, the subject of toxicity and such is practically irrelevant; if electroneutrality is
maintained at all time, in-vivo applications will not give rise to problems either.
In drug-loaded hollow fibres, the material used for the hollow fibre matrix is generally a conventional
material known to be non-toxic or non-carcinogenic, like polyurethane, nylon or polyethylene
vinylacetate copolymers [15-17]. The possible toxic effect thus lies in the drug inside the hollow fibre.
As drugs in high doses might have a toxic effect, it is crucial that the release patterns of the hollow
fibres do not give rise to such doses. Furthermore, the way the drug is incorporated in the fibre is
important. It is important to characterise their filling, because of possible biodegradability especially,
but also with regard to fibre damage..
For textile materials treated with nanoparticles, the base materials are common and well-known
textiles of both natural and synthetic origin. Hence, no toxicity is to be expected from them. By
selecting the appropriate polymer materials for encapsulating drugs and such, no toxicity is to be
expected thereof either. As nanoparticles are covalently bounded to the textile materials, they are thus
                                                
2 source: http://www.emscience.com/catalogs
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immobilised  in possible in-vivo applications; no harm will be caused by particles wandering
throughout the body.
For drug-loaded polymers, again the toxicity and carcinogenicity are determined by the choice of the
polymeric material. In the case of non-degradable polymers, no problems are to be expected, but for
biodegradable polymers, the degradation products should be non-toxic. Using materials such as
poly(glycolic acid), which have been thoroughly investigated on aspects such as toxicity, no problems
are to be expected for biodegradable polymers.
Biostability and biodegradability
For textile materials bearing cyclodextrins, the choice of the base material is decisive when concerning
biostability and biodegradability. Materials like cotton or wool are fairly biostable, though not
indefinitely [18]. In normal wear, body substances do not immediately damage them; mechanical
forces and things like weather, UV radiation and attack by microorganisms are the principal cause of
any damage. The materials’ lifetime can be enhanced by treatment of the finished materials to require
antibacterial, anti-insect or fungicidal effects, among others. Ultimately the materials will deteriorate,
and in that sense they are biodegradable. Synthetic materials (e.g. nylons, poly(ethylene terephtalate)
(PET)) are more biostable in that respect. The cyclodextrins themselves are readily biodegradable
[22].
In literature on the fixing of aza-crown ethers on textile materials [9], no comments were made on
changes in biodegradability. However, it is rather inappropriate to assume that introducing the aza-
crown ethers did not lead to any drastic changes in the biostability and biodegradability. For aza-crown
ethers in combination with silver ions, for example, the antimicrobial effects of the loaded groups might
be considered as enhancing long-term biostability. (Ultimate) biodegradability depends, again, on the
choice of the base material.
In literature concerning fullerene-treated textile material, no specific comments have been made on
biodegradability or biostability. As common materials form the base, these will mainly govern the
biodegradation pattern. As with aza-crown ethers, the fullerene groups can provide antimicrobial
effects (e.g. by complexation of silver ions), implying increased biostability.
For ion exchange fibres, biostability and biodegradability is largely influenced by the choice of the
base material. One such commercial available system is the Smopex® fibres. These materials, or at
least their polyethylene backbones, are non-degradable. Also, traditional textile materials such as wool
and cotton can be used – the biodegradability of these materials has been discussed before. The
large amount of electrically charged groups in the fibre is bound to have an influence on biostability
and biodegradability, although nothing is mentioned in the literature cited. It can easily be understood
that a change in the fibre‘s equilibrium situation will lead to a reactive system, more susceptible to
phenomena such as degradation. However, especially in ex-vivo applications such as textile
coverings, there is unlikely to be any large disturbance of the equilibrium other than the desired one,
which causes the release of the drug.
The biostability and biodegradability of a hollow fibre system depends on the material chosen for the
fibre wall. Of course, with a non-degradable material such as polyurethane, the fibre remains intact.
For some applications, especially in-vivo, biodegradability is desired, as it takes away the necessity to
surgically remove the system. In such cases, biodegradable materials such as poly(lactic acid) or
poly(glycolic acid) can be used. The choice of the material is very important, as biodegradation will
interfere with the release rate.
With nanoparticles, the biostability and biodegradability of the system is primarily determined by the
choice of the base material. As common textile materials form this, the same biostability and
biodegradability considerations hold as for cyclodextrin treated materials (among others). For in-vivo
applications, suitable materials have to be chosen, if they are desired to be biodegradable. The
polymer material used for encapsulating the drug is not really important with respect to biostability or
biodegradability of the systems as a whole. Practically all polymers are suitable for encapsulation,
though the choice of polymer is of influence in the release pattern of the particle [18]. When desired, a
biodegradable material can be chosen so that degradation will (partially) control the release of the
particles’ contents. A nanoparticle treatment is not limited to giving the textile material a drug releasing
capacity. By encapsulation of appropriate agents, for example anti-fungal or anti-insect, biostability
and non-degradability can be improved [18].
The biodegradability and biostability of the drug-loaded fibres is determined by use of the polymer.
Again, biostability is guaranteed when using well-known polymer materials such as polyethylene or
polyurethane. Though nothing has been mentioned in the literature, it is of course interesting to
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investigate whether solubilising the drug into the polymer has an effect on polymer properties, one of
which is biostability. For some polymer fibre systems, biostability is undesirable, as the release of the
drugs depends upon degradation. Hence, the material is designed to have a fair biodegradation rate,
e.g. by introduction of a large amount of ester linkages. Some control over the degradation rate can be
achieved by choosing the appropriate monomers.
Interface reactions
For cyclodextrin textiles, some tests are performed which consider irritating or sensitising effects [7]. It
should be borne in mind that there are several different cyclodextrins and derivatives, not all of which
have yet been tested with regard to these effects. With aza-crown ethers, unfortunately no specific
data was found on this aspect. For fullerenes, again, no comments were made in the literature. Based
upon safety data, one could expect some problems, as C60 is marked as being ‘irritating’3, and contact
with skin and eyes should be avoided. It is unclear how fixing and possible further complexation alters
this behaviour.
For ion-exchange fibres, only in-vitro (in-the-lab) tests have been performed so far, using human
cadaver skin [11], therefore no real statement can be made regarding possible interface reactions. It is
questionable whether the large amount of charged groups in the system might give rise to phenomena
such as skin irritation when the equilibrium is disturbed. As the latter is not likely to happen (in
preparing ion-exchange fibres, the fibres are washed with water a few times without leading to any
build-up of charge), no problems should be expected here.
With hollow fibres, irritation would stem from the choice of the fibre wall material. By choosing well-
known fibres, which are known not to cause bodily responses and to be comfortable to wear, irritation
is not an issue.
For textiles treated with nanoparticles, the textile materials themselves are unlikely to cause any
undesired effects, as they are common materials which people are used to. For drug encapsulation,
polymers with known, advantageous properties regarding interactions between the material and the
human tissue will have to be chosen. As the list of useful polymers is almost infinite, a suitable solution
for almost any situation is to be found [18].
As far as interface reactions are concerned, the drug-loaded fibres will present no problems as long as
polymers are chosen that are considered to be ‘safe’, such as polyethylene. Again, it might be
interesting to investigate the effect of drug solubilisation on polymer properties: one possibility would
be the occurrence of surface modifications, which could be disadvantageous in respect of interface
reactions. For biodegradable fibres, it is not only the fibre that might cause interface reactions, but also
the degradation products.
Controllability
The mechanism of drug release from cyclodextrin complexes has been investigated in several
experiments. An initial difficulty in making remarks on controllability is that practically every
cyclodextrin derivative has its own release pattern, as do combinations of cyclodextrins with different
drugs. This is due to the fact that the interactions governing the complexation strengths vary in every
case (as expressed by k1/k-1 in the formula below). The drug-cyclodextrin complexation and
decomplexation (release) is an equilibrium process of the type:
D1+CD D1-CD
k1
k-1
where D1 is the drug, CD the cyclodextrin and D1CD the drug-cyclodextrin complex. It is stated that for
weakly complexed drugs, dilution is controlling decomplexation, as it shifts the equilibrium. For more
strongly bound drugs in drug-cyclodextrin complexes, competitive displacement and protein drug
binding are important as well; the former shifting the equilibrium by decreasing the available amount of
free cyclodextrin, the latter by decreasing the available amount of the free drug [26]. The statements
above are based upon experiments dealing with non-fixed cyclodextrins in oral delivery systems. As
the fixation of cyclodextrins did not affect their complexing power, it can be reasoned that the release
                                                
3 source: http://www.chemexper.com/
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pattern is not influenced by the fixation either. However, a more detailed study on this topic is
desirable. In literature, some experiments in changing the release pattern have been reported. Again,
these concern non-fixed cyclodextrins. Two examples:
• Cyclodextrins can be used to overcome problems in drug solubilisation, e.g. water-insoluble drugs
can be solubilised. Release is then based on changing the environment, for example from
aqueous to lipophilic, and can be regarded as a ‘triggered’ release. Once triggered, the release is
immediate and without delay [5].
• Drug release can be delayed by using pH-sensitive systems, e.g. systems that are less soluble in
water at low pH, but soluble in neutral or alkaline regions due to the ionisation of an acidic group.
In oral administration, this means that drug release can be delayed until the complexes have
passed the stomach and reached the smaller intestine [5].
Unfortunately, no general rules concerning drug release can be derived from this kind of information. It
can be stated that it is a question of ‘trial and error’ – that is, for a given situation, a particular complex
has to be found which will give the desired pattern. For ex-vivo applications, it must therefore be
concluded that once a combination of drug and cyclodextrin is chosen, the release pattern is fairly well
set, unless a multi-layer system is created.
For aza-crown ether textiles, few comments can be made regarding the controllability of the system,
as no real delivery takes place. It is however essential to investigate the possibility of the migration of
the complexed ions (which was suggested in antimicrobial tests), and its effect on phenomena such as
interface reactions. For fullerene systems, the same statement applies.
With ion-exchange fibres, the release pattern can be changed in several ways. An example: to
activate Smopex® fibres, i.e. to create ionic groups, fibres were treated with NaCl. When a mixture of
NaCl and NaOH was used, it appeared that drug binding increased, though the fraction of the drug
content released was the same. Hence, increased drug release can be achieved by appropriate
activation, though this leads to relatively greater drug wastage [11]. The drug release increased with a
decrease in electrolyte concentration (the ‘helper’), which can be explained by considering the drug
equilibrium. It must be emphasised that the decreasing electrolyte concentration is a result of
increased external volume: when the same amount of electrolyte is used, the external volume will be
much higher in the case of lower concentrations. Hence, equilibrium is shifted towards release.
However, the decreased electrolyte concentration increases the electrostatic affinity between the drug
and the fibre. Apparently, the tendency to re-establish the drug equilibrium is the predominant effect.
The opposite situation would be observed if the same external volume would be used for the different
electrolyte concentrations, because in this case the shift in equilibrium would not be that great, and the
affinity effect will be overriding [11]. Changes in the electrolyte can help to increase drug release.
When CaCl2 was used in combination with NaCl instead of NaCl alone, drug release is increased due
to the stronger tendency of Ca2+ to bind to the ion exchange groups. This effect appears to be pH-
dependent [11]. To summarise, drug release can be controlled to some extent by choosing the
appropriate fibre-drug combination and by changes in the electrolyte solution, concentration, and
composition as well as pH. In order to extend control over the release pattern of the drug from the
fibre, so-called iontophoresis can be used. This method, in which the fibres are placed in an electric
cell and subjected to an electric current, can be useful in releasing drugs that are not released in a
passive way [2]. Furthermore, forced exchange can be used to overcome the large biological
variations that can exist between patients. The strength of current can be used in controlling the
release rate.
For hollow fibres, the fibre membrane usually controls the release. Several types of polymeric-
controlled release systems have been developed for commercial applications. These can be
categorised in three basic types, regarding the rate-controlling mechanism: diffusion-controlled,
chemical reaction-controlled and solvent activation-controlled. Most control systems use one ore more
of these mechanisms. Much attention has been paid to the mathematic modelling of controlled release
from hollow fibres [27-29]. These mathematical treatments are beyond the scope of this review. With
the drug present in the crystal state, the concentration of the dissolved drugs is determined by its
saturation solubility. In this case, the release rate can be controlled by the thickness and permeability
of the fibre membrane. As a consequence, this concept can only be used to control the release of a
single drug [16]. When the release of more than one drug is to be controlled, it is necessary to
dissolve the drugs completely. In this way, the release can be controlled independently by the
concentration of each drug and by the membrane characteristics. The release is then influenced by
the solubility and diffusion coefficient of a drug in the core polymer [17]. If a constant release is
desired, the permeability of the bulk polymer (the core) for a specific drug should be much higher than
the membrane permeability. Thus, by choosing the appropriate membrane material and thickness, a
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specific release pattern can be established. However, once this is set, no further means of control
remain. When release is not only diffusion-controlled, changes in the release environment (e.g.
changes in solvent composition) can be used to control drug release.
With nanoparticles, the architecture of the particle shell or matrix can be formulated and fine-tuned to
exhibit the controlled release of its contents, ranging from constant but prolonged release to zero
release. The particle can be formulated with an almost infinite degree of designed characteristics via
key structural features, such as cross-linking density, hydrophilic-hydrophobic balance of the
copolymer units and the stiffness of the polymer network. Furthermore, erodible or biodegradable
particles can be used to combine the release mechanisms of diffusion and erosion. In addition, the
particles can be designed to respond to different stimuli to alter the rate of release. The polymers can
be induced to undergo a distinct thermodynamic transition by the adjustment of any of a number of
environmental parameters, e.g. pH, temperature, ionic strength, co-solvent composition, pressure or
electric field. Examples are polymers that, based on the lower critical solution temperature transition,
drastically cut off release when exposed to higher temperatures [18].
With fibres which incorporate the drug within, some control over drug release can be introduced by
varying the choice of polymer used in the fibre (influencing drug diffusion), the diameter of the
polymeric fibres (controlling diffusion distance), the concentration of polymer used in the fibre
(influencing fibre structure) and the amount of drug loaded in the fibre (influencing concentration
gradients) and biodegradability of the polymer (fast biodegradation enhancing drug release). Of
course, these variables only apply to situations where the drug is located within the polymer fibre. The
drug-loaded fibres can be combined with non-loaded fibres, either biodegradable or non-degradable,
which can be used to change the distance over which a drug has to diffuse before it is set free into the
body/onto the skin (among other factors), which hence constitutes another means of controlling drug
release [19]. A release pattern is fixed once the fibre is prepared. As a final remark, it can be said that
creating a proper release system is more or less a question of trial and error, as various drugs
interfere differently with various polymers.
Material costs
For the textile materials treated with cyclodextrins, the base materials can be common textiles such as
cotton, cellulosic or synthetic fibres such as PET. There is no need for pre-treatment of these
materials, and hence, in comparing the system with other systems, the material costs are mainly
determined by the cyclodextrins. Research in the cyclodextrin area has grown, leading to numerous
publications and patents [7]. Biotechnological advancements have led to great improvements in
cyclodextrin production, lowering production costs [3]. This phrasing can be used to assume that
cyclodextrins, at least the parent ones (α-, β- and γ-dextrin) will have acceptable costs. Besides – and
this should be emphasised – at least for ex-vivo, non-biodegradable materials, the cyclodextrins can
be reloaded and hence the material can be recycled. In Table 1 a rough idea of the market prices of
cyclodextrins is given:
Table 1. Market prices of different cyclodextrins (2002)
Natural Cyclodextrins Pricesa
α-cyclodextrin 99% 5g €18.48
β-cyclodextrin 99% 5g €9.24
γ-cyclodextrin 99% 5g €130.90
Neutral Modified Cyclodextrins
β-dimethyl cyclodextrin 5g €150.92
β-trimethyl cyclodextrin 5g €831.60
β-2-hydroxypropyl cyclodextrin 5g €150.92
Ionic Modified Cyclodextrins
β-cyclodextrin phosphate 2.5g €485.10
β-carboxy methyl cyclodextrin 5g €121.66
β-amino cyclodextrin 5g €2710.40
(source: http://www.capital-hplc.co.uk/cdex.htm),
aOriginal prices in British pounds; exchange rate taken as £1 =€1.54
As can be seen in this table, when moving from unmodified to modified cyclodextrins, the prices
rapidly increase. Unfortunately, for fixation upon textile materials using common textile-finishing
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techniques, modification is a necessity. For medical applications, these costs might be acceptable.
One should further bear in mind that the quantities mentioned in Table 1 are lab-scale quantities. For
other applications, e.g. delivery of fragrances4, the prices will have to drop. Thus, the desire to use
cyclodextrins for other than medical applications might lead to even lower prices, due to further
development and increased production, with large quantity sales.
Because of the relative cheapness of the base materials, the material costs of aza-crown ether treated
textiles are mainly determined by the prices of the aza-crown ethers. As an indication, the market price
of the aza-crown ethers, ACE (22) and ACE (22DD), used in literature can be taken: €53 and €212 for
one gram, respectively5. This is considerably higher than the prices of cyclodextrin; besides, only anti-
microbial activity without drug delivery capacity is achieved, making the material even more expensive
in relative terms.
For fullerenes, again the main cost-determining factor is the fullerenes themselves. Some indications
can be found on the Internet: market prices vary from €1756 to €2126 for 5g C60, 99.5% pure and
€3047 to €9017 for 5g C60, ultra pure (>99.95%). Furthermore, in the fixation process γ-cyclodextrins
turned out to be a useful solubilising agent, but as was shown, these materials are not very cheap.
In ion-exchange fibre systems, the textile material itself is the drug carrier. As mentioned, several ion-
exchange fibres are available, e.g. the Smopex® range, based on grafted polyethylene. It is to be
expected that these specialty fibres exceed the ordinary textiles in costs. However ordinary textiles
such as cotton, can also be used to create exchange fibres. Besides, no extra carrier group is needed:
once it is spun, the fibre is capable of carrying drugs, albeit that it has to be activated in order to create
ionic groups. As the latter can be achieved by fairly simple salt solutions, this will not be of especial
relevance when considering costs. The necessity for a release ‘helper’ might be disadvantageous,
since this demands a different textile setup (e.g. the need for an extra electrolyte reservoir).
For drug-loaded hollow fibres, the costs can be divided. Of course, there are the costs of the fibre
itself. It can be reasoned that producing hollow fibres demands more sophisticated techniques, which
will show in the costs. Strictly speaking, this falls within the aspect of the manufacturing process and
costs, and should not be taken into account here. As the fibre material can consist of common
polymers, high costs are not to be expected thereof. As for the filling, it depends on how the drug is to
be bound inside the fibre. Some alternatives, such as a polymer gel or crystallisation in combination
with other substances, will give rise to additional material costs.
With nanoparticle-treated textiles, a great advantage concerning material costs is the ability to use
common textiles as base materials, and thus, again, no great impact on material costs is to be
expectedas a result. For nanoparticle synthesis, a broad range of materials is available, including the
common ones. Not all of them are qualified as bulk polymers [18]. For specific polymer coatings, with
specific release properties, costs can therefore rise.
The material costs in creating drug-loaded fibres are determined by the choice of the polymer. As
common polymers such as polyethylene can be used, systems do not necessarily have to be
expensive. When considering the material costs for the biodegradable polymers in which the drug is to
be incorporated in the main chain, the drug itself should not be taken into account, as was not done in
the other systems. Hence, only the other polymer ingredients, i.e. the monomers, basically form the
material costs. Whether the system is costly or not thus depends on whether the monomers are bulk
(and hence ‘cheap’) or not.
Manufacturing process
A major advantage immediately follows from the way the cyclodextrin-textile system is prepared. The
attachment of the cyclodextrin groups is achieved by relatively simple and well-developed textile
treatment techniques [8]. Furthermore, which may be even more important, it is possible to treat an
already fabricated piece of cloth [4, 6]. Hence, the manufacture of the textile material can be
separated from the actual system formation, offering the possibility of specialisation without having to
deal with the problems concerned with textile production. A second advantage of the possibility of
treating finished textiles is that it can be guaranteed that the cyclodextrin groups are mainly attached
to the textile surface that will form the interface with (for example) the skin. Hence, the majority of the
original drug-loading capacity is maintained, in contrast with preparing cloth from treated fibres. As a
                                                
4 which can also be achieved with cyclodextrin treated textiles
5 source: http://www.emscience.com/catalogs - original price in dollars; exchange rate taken $1 = €1.06
6 source: http://www.mtr-ltd.com/pricelist.htm - - original price in dollars, exchange rate taken $1 = €1.06
7 source: http://www.sesres.com/FullerenesPrices.asp - original price in dollars, exchange rate taken $1 = €1.06
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final remark considering manufacture, it can be stated that only one textile treatment is necessary to
create a feasible, drug-loadable system; this in comparison with the traditional multi-phase systems, in
which separate layers have to be created [1]. For aza-crown ether textiles, the comments made above
also apply.
For fullerene-treated textiles, the manufacturing process is, again, relatively simple, though techniques
different from the conventional ones for textile treatment are used, which can be seen as a
disadvantage. Besides, the fixation process takes more time in the case of fullerenes compared for
example to cyclodextrins. In the examples, for cyclodextrins, preparation times were in the order of
minutes to a few hours [4, 6], whereas in the case of fullerenes, fixation took a day or even more [10].
With ion-exchange fibres, the activation step can also be considered as being a disadvantage in the
fabrication process, when the latter is considered as being the complete processleading to a system
ready for drug loading. Nevertheless, as ion-exchange fibres are used in applications other than
medical, e.g. wastewater treatment, removing metal out of liquors and such, it can be stated that the
production of such fibres has passed the developmental stage and is now commercially attractive.
This is stressed by the use of the ion exchange fibres found in the literature, which were commercially
available.
The fabrication of many types of hollow fibres has developed in such a way that no great difficulties
and hence no extreme costs are nowadays to be expected thereof. However, the hollow fibres have a
great disadvantage in comparison with the other systems discussed so far, namely the coupling of
loading the fibre to the manufacture in some cases, e.g. in the case of the drug crystals in the polymer
core. This calls for specialisation, in the sense that those producing the fibres will also have to have a
range of different drugs at their disposal.
With nanoparticle treatment, a great advantage is that it is applicable to both fibres and finished goods
[18]. Thus, as with cyclodextrins, the specific treatment in order to get useful drug delivery systems
can be decoupled from the fabric production. Furthermore, the application of the nanoparticles to the
system can be achieved by known textile treatment techniques, which is also advantageous.
With fibres with drugs in their embodiment, the fabrication costs are of no real interest, as the
techniques used are fairly simple. A far more interesting point is the fact that the drug is incorporated
into the fibre while processing the fibre. As was mentioned with the hollow fibre systems, this is rather
disadvantageous, as it calls for the availability of both polymers and various drugs on one production
location.
System comparison
In the foregoing paragraphs, a number of textile delivery systems are discussed. As to be expected,
some of them look more promising than others. Moreover, further development is desirable. In this
paragraph, the systems’ “weak spots” are discussed again, but now in comparison with other systems.
Concerning the aspect of toxicity, carcinogenicity and such, no real distinction is to be made between
the systems, at least not based on the literature cited. The real toxicity stems from the drugs used
themselves; this should not be taken into account, as it is virtually the same for all cases. It has been
mentioned that especially in the case of the aza-crown ethers and fullerenes, additional research is
desirable.
For biodegradability and biostability, the same statement holds. On the other hand, based on
literature, the combination of cyclodextrins, aza-crown ethers and fullerenes with textile materials is to
be applied more in the field of ex-vivo than in-vivo delivery systems. This is underlined by the textile
base materials used, which are all representatives of those materials used in common clothing. In
order to take advantage of the ability of system regeneration, in-vivo applications are even more ‘out
of the picture’. Biodegradable systems, which are more interesting for in-vivo applications, have not
yet been explored. The same goes for nanoparticle treatment, which has been rather restricted to
common textiles. As for the ion-exchange fibres, it is to be expected that these systems will consist
mainly of non-degradable fibres, when considering the treatments these materials are subjected to.
However, it is interesting  to explore the concept of combining biodegradable textile materials with
cyclodextrins and nanoparticles, especially for in-vivo use. As an example: can the same fixating
principles and treatment processes be used in combination with biodegradable polymers?
In-vivo biodegradable applications are more likely to come into view when using hollow fibre systems,
drug-loaded polymers or polymers containing a drug in their backbone.
As for the interface reactions, it can be stated that the data in the literature cited is insufficient to make
substantial comments, and no real comparison can be made here. It can be stated that at least the
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cyclodextrin, nanoparticle, hollow-fibre system and some of the drug-loaded fibre systems can be
freed of irritating effects. For the other systems, interface reaction experiments are desirable.
As for material costs, the most interesting systems will probably be those using the common textile
materials as its base, such as the cyclodextrin system and the nanoparticle system. To some extent,
the ion exchange system can be mentioned here too, as it was shown that it is possible to graft
common textile materials with ion-exchange groups.
In fabrication, the cyclodextrin and nanoparticle systems will also be economically of most interest, as
they can be prepared by using common textile-treatment techniques. As no further information was
found on the grafting of textiles in order to get ion exchange fibres, no real comments can be made on
this point. It is interesting, though, to have a further look at these systems, because ion exchange
fibres are promising with respect to other aspects as well, especially controllability.
Since little distinction could be made between the systems by considering all aspects except
controllability, the latter can be considered to be the most important aspect. As mentioned, for most
systems release patterns can be controlled in their preparation, but once prepared, the release pattern
is fixed. The only two real exceptions are the ion-exchange fibres and the nanoparticle systems.
These systems could be controlled afterwards by means of such factors as electrolyte composition (in
case of the exchange fibres) or pH. The most interesting systems at this point would therefore be the
ion-exchange fibre system and the nanoparticle-treated textile systems.
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